Apollomics, Inc. (APLM)
- Previous Close
0.4059 - Open
0.4051 - Bid --
- Ask --
- Day's Range
0.3950 - 0.4054 - 52 Week Range
0.3880 - 6.4500 - Volume
153,431 - Avg. Volume
176,570 - Market Cap (intraday)
35.494M - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.
www.apollomicsinc.comRecent News: APLM
Performance Overview: APLM
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLM
Valuation Measures
Market Cap
36.98M
Enterprise Value
3.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.76%
Return on Equity (ttm)
--
Revenue (ttm)
821k
Net Income Avi to Common (ttm)
-172.6M
Diluted EPS (ttm)
-2.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
37.82M
Total Debt/Equity (mrq)
11.30%
Levered Free Cash Flow (ttm)
-23.72M
Research Analysis: APLM
Company Insights: APLM
APLM does not have Company Insights